Geron Corporation
Clinical trials sponsored by Geron Corporation, explained in plain language.
A biopharmaceutical company developing therapies for hematologic malignancies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental drug combo aims to tame bone marrow cancer Results expected Feb 2027 (estimated)
-
Experimental drug combo aims to tame bone marrow cancer
Disease control OngoingThis early-stage trial tests two drugs—imetelstat and ruxolitinib—together in people with myelofibrosis, a type of bone marrow cancer. The study has two parts: first, finding a safe dose of the combination, and second, checking if it improves symptoms like fatigue and spleen disc…
Phase 1 • Sponsor: Geron Corporation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug may free MDS patients from frequent blood transfusions
Disease control OngoingThis study tests a drug called imetelstat in adults with a bone marrow disorder (MDS) who currently need regular red blood cell transfusions because standard treatments have stopped working. The main goal is to see if the drug can help patients go 8 weeks or more without a transf…
Phase 2/3 • Sponsor: Geron Corporation • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for myelofibrosis patients who fail current treatments
Disease control OngoingThis phase 3 trial tests a drug called imetelstat against the best available treatments for people with advanced myelofibrosis whose disease has stopped responding to JAK inhibitors. The study includes 327 participants and aims to see if imetelstat can help them live longer and f…
Phase 3 • Sponsor: Geron Corporation • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC